How The Eton Pharmaceuticals (ETON) Story Is Shifting With Hemangeol And New Valuation Targets [Yahoo! Finance]
Eton Pharmaceuticals, Inc. (ETON)
Last eton pharmaceuticals, inc. earnings: 3/5 04:02 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Eton Pharmaceuticals is back in focus after an updated consolidated fair value estimate moved from US$30 to about US$39.33 per share. That shift sits at the center of current analyst debate, with bullish and bearish views largely hinging on how the Hemangeol acquisition and related execution risks compare with the new pricing framework. Read on to see what is driving the evolving story around these targets and how you can keep track as the narrative shifts. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Eton Pharmaceuticals. What Wall Street Has Been Saying ?? Bullish Takeaways Craig-Hallum raised its Eton Pharmaceuticals price target to US$30 after the Hemangeol deal, describing the acquisition of U.S. rights as attractive and accretive in the near term. Craig-Hallum highlights Hemangeol as the only FDA approved treatment for infantile hemangioma, with about US$12m in U.S. sales in 2025, and points to a
Show less
Read more
Impact Snapshot
Event Time:
ETON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ETON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ETON alerts
High impacting Eton Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ETON
News
- Eton Pharmaceuticals (ETON) was upgraded by Zacks Research from "hold" to "strong-buy".MarketBeat
- Eton Pharmaceuticals (ETON) had its price target raised by HC Wainwright from $37.00 to $52.00. They now have a "buy" rating on the stock.MarketBeat
- Eton Pharmaceuticals (ETON) had its price target raised by B. Riley Financial, Inc. from $26.00 to $31.00. They now have a "buy" rating on the stock.MarketBeat
- Eton Pharmaceuticals (ETON) had its price target raised by Craig Hallum from $30.00 to $35.00. They now have a "buy" rating on the stock.MarketBeat
- Eton Pharmaceuticals Inc (ETON) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]Yahoo! Finance
ETON
Earnings
- 3/19/26 - Beat
ETON
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/19/26 - Form 8-K
- 3/19/26 - Form 10-K
- ETON's page on the SEC website